Skip to main navigation Skip to search Skip to main content

COMP360 Psilocybin Therapy Shows Potential In Open-Label Study In Type II Bipolar Disorder Presented At ACNP

Press/Media

Period8 Dec 2022

Media coverage

1

Media coverage

  • TitleCOMP360 Psilocybin Therapy Shows Potential In Open-Label Study In Type II Bipolar Disorder Presented At ACNP
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date8/12/22
    PersonsLei Zhang
View all 1
View less